Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Keiji Yamamoto is active.

Publication


Featured researches published by Keiji Yamamoto.


Journal of Pharmacological and Toxicological Methods | 2011

Safety pharmacology in 2010 and beyond: Survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society

Alan S. Bass; Hugo M. Vargas; Jean-Pierre Valentin; Lewis B. Kinter; Tim Hammond; Rob Wallis; Peter K. S. Siegl; Keiji Yamamoto

In recognition of the tenth anniversary of the Safety Pharmacology Society (SPS), this review summarizes the significant events of the past 10years that have led to the birth, growth and evolution the SPS and presents a roadmap to the immediate-, intermediate- and long-term future of the SPS. The review discusses (i) the rationale for an optimal non-clinical Safety Pharmacology testing, (ii) the evolution of Safety Pharmacology over the last decade, (iii) its impact on drug discovery and development, (iv) the merits of adopting an integrated risk assessment approach, (v) the translation of non-clinical findings to humans and finally (vi) the future challenges and opportunities facing this discipline. Such challenges include the emergence of new molecular targets and new approaches to treat diseases, the rapid development of science and technologies, the growing regulatory concerns and associated number of guidance documents, and the need to train and educate the next generation of safety pharmacologist.


Stem cell reports | 2017

Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes

Tadahiro Shinozawa; Koki Nakamura; Masanobu Shoji; Maya Morita; Maya Kimura; Hatsue Furukawa; Hiroki Ueda; Masanari Shiramoto; Kyoko Matsuguma; Yoshikazu Kaji; Ippei Ikushima; Makoto Yono; Shyh-Yuh Liou; Hirofumi Nagai; Atsushi Nakanishi; Keiji Yamamoto; Seigo Izumo

Summary To predict drug-induced serious adverse events (SAE) in clinical trials, a model using a panel of cells derived from human induced pluripotent stem cells (hiPSCs) of individuals with different susceptibilities could facilitate major advancements in translational research in terms of safety and pharmaco-economics. However, it is unclear whether hiPSC-derived cells can recapitulate interindividual differences in drug-induced SAE susceptibility in populations not having genetic disorders such as healthy subjects. Here, we evaluated individual differences in SAE susceptibility based on an in vitro model using hiPSC-derived cardiomyocytes (hiPSC-CMs) as a pilot study. hiPSCs were generated from blood samples of ten healthy volunteers with different susceptibilities to moxifloxacin (Mox)-induced QT prolongation. Different Mox-induced field potential duration (FPD) prolongation values were observed in the hiPSC-CMs from each individual. Interestingly, the QT interval was significantly positively correlated with FPD at clinically relevant concentrations (r > 0.66) in multiple analyses including concentration-QT analysis. Genomic analysis showed no interindividual significant differences in known target-binding sites for Mox and other drugs such as the hERG channel subunit, and baseline QT ranges were normal. The results suggest that hiPSC-CMs from healthy subjects recapitulate susceptibility to Mox-induced QT prolongation and provide proof of concept for in vitro preclinical trials.


Journal of Pharmacological Sciences | 2005

QT PRODACT: In Vivo QT Assay in the Conscious Dog for Assessing the Potential for QT Interval Prolongation by Human Pharmaceuticals

Shigeki Toyoshima; Akihiro Kanno; Tetsuya Kitayama; Koji Sekiya; Keiko Nakai; Masao Haruna; Terumasa Mino; Hiroyasu Miyazaki; Koji Yano; Keiji Yamamoto


Journal of Pharmacological Sciences | 2005

QT PRODACT: In Vivo QT Assay With a Conscious Monkey for Assessment of the Potential for Drug-Induced QT Interval Prolongation

Toshiyasu Hombo; Akihiro Kanno; Hironobu Ikeda; Masakazu Imaizumi; Noritsugu Shimizu; Kengo Sakamoto; Shin-ichi Kitani; Yoshinori Yamamoto; Shingo Hizume; Keiko Nakai; Tetsuya Kitayama; Keiji Yamamoto


Journal of Pharmacological Sciences | 2005

QT PRODACT: Comparison of Non-clinical Studies for Drug-Induced Delay in Ventricular Repolarization and Their Role in Safety Evaluation in Humans

Takeshi Omata; Chieko Kasai; Munehiro Hashimoto; Toshiyasu Hombo; Keiji Yamamoto


Journal of Pharmacological Sciences | 2005

QT PRODACT: a multi-site study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles.

Seiji Hayashi; Yoshihide Kii; Mitsuyasu Tabo; Hitoshi Fukuda; Tetsuji Itoh; Takashi Shimosato; Hideto Amano; Mamoru Saito; Hajime Morimoto; Kiyoshi Yamada; Atsuhiro Kanda; Toshimasa Ishitsuka; Takanobu Yamazaki; Yoichi Kiuchi; Shinya Taniguchi; Tatsuya Mori; Shigekazu Shimizu; Yuji Tsurubuchi; Shun-ichi Yasuda; Shin-ichi Kitani; Chiaki Shimada; Kazuo Kobayashi; Masaharu Komeno; Chieko Kasai; Toshiyasu Hombo; Keiji Yamamoto


Journal of Pharmacological Sciences | 2005

QT PRODACT: In Vivo QT Assay in Anesthetized Dog for Detecting the Potential for QT Interval Prolongation by Human Pharmaceuticals

Hiroyuki Tashibu; Hiroyasu Miyazaki; Kumiko Aoki; Yasuki Akie; Keiji Yamamoto


Journal of Pharmacological Sciences | 2005

QT PRODACT: Inter-facility Variability in Electrocardiographic and Hemodynamic Parameters in Conscious Dogs and Monkeys

Hiroyuki Sasaki; Noritsugu Shimizu; Hideki Suganami; Keiji Yamamoto


Journal of Pharmacological Sciences | 2005

QT PRODACT: Sensitivity and Specificity of the Canine Telemetry Assay for Detecting Drug-Induced QT Interval Prolongation

Hiroyasu Miyazaki; Hiroyuki Watanabe; Tetsuya Kitayama; Masahiro Nishida; Yasuhiro Nishi; Koji Sekiya; Hideki Suganami; Keiji Yamamoto


Journal of Pharmacological Sciences | 2005

QT PRODACT: evaluation of the potential of compounds to cause QT interval prolongation by action potential assays using guinea-pig papillary muscles.

Yoshihide Kii; Seiji Hayashi; Mitsuyasu Tabo; Takashi Shimosato; Hitoshi Fukuda; Tetsuji Itoh; Hideto Amano; Mamoru Saito; Hajime Morimoto; Kiyoshi Yamada; Atsuhiro Kanda; Toshimasa Ishitsuka; Takanobu Yamazaki; Yoichi Kiuchi; Shinya Taniguchi; Tatsuya Mori; Shigekazu Shimizu; Yuji Tsurubuchi; Shun-ichi Yasuda; Shin-ichi Kitani; Chiaki Shimada; Kazuo Kobayashi; Masaharu Komeno; Chieko Kasai; Toshiyasu Hombo; Keiji Yamamoto

Collaboration


Dive into the Keiji Yamamoto's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Takashi Shimosato

Shiga University of Medical Science

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kazuo Kobayashi

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mitsuyasu Tabo

Chugai Pharmaceutical Co.

View shared research outputs
Researchain Logo
Decentralizing Knowledge